| Manufacture of compounds and compositions for inhibiting the activity of shp2 |
2023-7-17 |
2023-9-01 |
|
| LFA-1 inhibitor and polymorph thereof |
2023-7-04 |
2023-7-27 |
|
| Ophthalmic emulsion |
2023-5-18 |
2023-9-14 |
|
| Multifocal lens having reduced chromatic aberrations |
2023-5-10 |
2023-9-07 |
|
| Methods of making chimeric antigen receptor -expressing cells |
2023-5-08 |
2023-5-25 |
|
| Heat tunable intraocular lens |
2023-4-25 |
2023-8-17 |
|
| Systems and methods for intraocular lens selection |
2023-4-13 |
2023-8-10 |
|
| Treatment of cancer using anti-CD19 chimeric antigen receptor |
2023-4-05 |
2023-6-20 |
|
| Biomarkers and CAR T cell therapies with enhanced efficacy |
2023-3-28 |
2023-6-13 |
|
| CAR T cell therapies with enhanced efficacy |
2023-3-15 |
2023-6-01 |
|
| Specific sites for modifying antibodies to make immunoconjugates |
2023-3-06 |
2023-8-31 |
|
| Compositions and methods for immunooncology |
2023-2-27 |
2023-4-13 |
|
| Cancer treatment using multispecific chimeric t-cell receptor protein |
2023-2-17 |
2023-5-23 |
|
| Bcma chimeric antigen receptors and uses thereof |
2023-2-17 |
2023-6-15 |
|
| Dispensing device |
2023-2-17 |
2023-6-29 |
|
| Human mesothelin chimeric antigen receptors and uses thereof |
2023-2-16 |
2023-5-11 |
|
| Cd20 therapies, cd22 therapies, and combination therapies with cd19 chimeric … |
2023-2-09 |
2023-5-12 |
|
| Regulatable chimeric antigen receptor |
2023-2-08 |
2023-5-12 |
|
| Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
2023-1-20 |
2023-5-02 |
|
| Compositions and methods for treatment of hemoglobinopathies |
2023-1-06 |
2023-4-11 |
|
| Treatment of cancer using a cd123 chimeric antigen receptor |
2022-12-30 |
2023-7-13 |
|
| Binding molecules against bcma and uses thereof |
2022-12-28 |
2023-7-07 |
|
| Delivery of RNA to trigger multiple immune pathways |
2022-12-13 |
2023-9-19 |
2023-9-19 |
| Immunization of large mammals with low doses of rna |
2022-12-13 |
2023-5-04 |
|
| Compositions and methods for antibodies targeting EPO |
2022-12-09 |
2023-3-07 |
|
| Syringe |
2022-12-09 |
2023-4-13 |
|
| Silicone hydrogel lens with a crosslinked hydrophilic coating |
2022-11-21 |
2023-5-25 |
|
| Sustained release delivery systems comprising traceless linkers |
2022-11-11 |
2023-6-29 |
|
| Novel pharmaceutical composition |
2022-11-08 |
2023-1-24 |
|
| COMPOSITE OF IL-15 AND IL-15Ra, AND USE OF THE SAME |
2022-10-28 |
2023-1-31 |
|
| Asciminib or a pharmaceutically acceptable salt thereof, such as asciminib … |
2022-10-26 |
2022-12-07 |
|
| Liposomes comprising lipid having pka value advantageous for rna delivery |
2022-10-21 |
2023-1-10 |
|
| Chimeric antigen receptors for the treatment of cancer |
2022-10-06 |
2023-1-24 |
|
| Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing … |
2022-10-03 |
2023-2-16 |
|
| Antibody molecules to pd-1 and uses thereof |
2022-9-26 |
2022-12-06 |
|
| Methods for improving the efficacy and expansion of chimeric antigen receptor- … |
2022-9-16 |
2022-11-10 |
|
| Cancer treatment using humanized anti-egfrviii chimeric antigen receptor |
2022-9-16 |
2022-12-27 |
|
| 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
2022-9-13 |
2022-10-06 |
|
| Pharmaceutical combination comprising alk inhibitor and shp2 inhibitor |
2022-9-07 |
2022-12-13 |
|
| Granules or granulated mixture, as well as pharmaceutical preparations … |
2022-9-02 |
2009-4-24 |
|
| 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors |
2022-8-18 |
2023-6-22 |
|
| 1-(4-{1-[(e)-4-cyclohexyl-3-trifluoromethylbenzyloxyimino]-ethyl}-2-ethyl- … |
2022-8-10 |
2022-12-22 |
|
| Treatment and prevention of cytokine release syndrome using chimeric antigen … |
2022-7-29 |
2022-11-01 |
|
| Compositions and methods for treatment |
2022-7-27 |
2023-7-27 |
|
| Methods for treating ocular diseases |
2022-7-27 |
2022-9-29 |
|
| Intermittent dosing of mdm2 inhibitor |
2022-7-25 |
2023-3-23 |
|
| Dimerization switches and uses thereof |
2022-7-22 |
2022-12-01 |
|
| Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof |
2022-7-21 |
2022-12-01 |
|
| Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor … |
2022-7-11 |
2023-1-05 |
|
| Compositions and methods for selective protein expression |
2022-7-08 |
2022-10-19 |
|
| Intraocular lens injector |
2022-7-07 |
2022-10-27 |
|
| Interleukin-17 (il-17) antagonistic antibodies |
2022-7-07 |
2023-7-27 |
|
| Rsv immunization regimen |
2022-6-24 |
2023-3-09 |
|
| 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and … |
2022-6-24 |
2022-11-03 |
|
| Rsv f protein compositions and methods for making same |
2022-6-23 |
2022-10-27 |
|
| Pre-fusion rsv f antigens |
2022-6-23 |
2022-10-20 |
|
| Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H- … |
2022-6-23 |
2023-5-09 |
2023-5-09 |
| Composition of therapeutic low-density lipoprotein-associated protein 6 (lrp6) … |
2022-6-22 |
2022-9-21 |
|
| Pyrazolyl derivatives useful as anticancer agents |
2022-6-15 |
2022-6-30 |
|
| Vibration systems and methods |
2022-6-15 |
2023-4-06 |
|
| Process for producing contact lenses with durable lubricious coatings thereon |
2022-6-07 |
2022-9-22 |
|
| Biomarkers predictive of therapeutic responsiveness to chimeric antigen … |
2022-6-07 |
2022-6-23 |
|
| Sustained release formulation comprising octreotide and two or more polylactide … |
2022-6-07 |
2022-9-22 |
|
| Immunomodulation by IAP Inhibitors |
2022-6-06 |
2022-9-22 |
|
| Antibody drug conjugates for ablating hematopoietic stem cells |
2022-6-06 |
2022-9-29 |
|
| Organic compounds |
2022-5-19 |
2022-9-01 |
|
| Intraocular lenses having zone-by-zone step height control |
2022-5-17 |
2022-9-01 |
|
| Factor XI Antibodies and Methods of Use |
2022-5-13 |
2022-8-09 |
|
| Silicone hydrogel contact lenses |
2022-5-12 |
2022-9-01 |
|
| Method of manufacturing bispecific antibodies, bispecific antibodies and … |
2022-5-11 |
2022-8-09 |
|
| Ocular implant with stiffness qualities, methods of implantation and system |
2022-4-28 |
2022-8-11 |
|
| Methods for treating liver disorders using fxr agonists |
2022-4-26 |
2022-10-06 |
|
| Dosage regimen for s1p receptor agonist |
2022-4-21 |
2022-7-07 |
|
| Systems, apparatuses, and methods for the optimization of laser … |
2022-4-19 |
2022-8-04 |
|
| Compositions and methods for the treatment of hemoglobinopathies |
2022-4-19 |
2022-5-12 |
|
| Medical container with nfc antenna |
2022-4-15 |
2022-8-18 |
|
| Methods of treating or ameliorating metabolic disorders using growth … |
2022-4-14 |
2022-8-11 |
|
| Novel formulations |
2022-4-12 |
2022-7-20 |
|
| Compounds and compositions for treating conditions associated with NLRP … |
2022-4-01 |
2023-9-19 |
2023-9-19 |
| Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the … |
2022-3-30 |
2022-7-28 |
|
| Fatty acids and their uses in conjugation to biomolecules |
2022-3-29 |
2022-6-28 |
|
| Monoclonal antibodies and methods of use |
2022-3-24 |
2022-8-11 |
|
| Treatment of cancer using humanized anti cd19 chimeric antigen receptor |
2022-3-23 |
2022-4-14 |
|
| Composition for immunizing against staphylococcus aureus |
2022-3-16 |
2022-5-24 |
|
| Antibody molecules to cd73 and uses thereof |
2022-3-15 |
2023-2-09 |
|
| Combination therapy of chimeric antigen receptor and pd-1 inhibitor |
2022-3-09 |
2022-6-14 |
|
| Virion-like delivery particles for self-replicating rna molecules |
2022-3-01 |
2022-6-23 |
|
| Viral vectors for treatment of retinal dystrophy |
2022-3-01 |
2022-6-14 |
|
| Antibody molecules to lag-3 and uses thereof |
2022-2-22 |
2022-6-07 |
|
| Computer method and system for deriving cell-to-cell spatial proximities |
2022-2-14 |
2023-9-05 |
2023-9-05 |
| Choline Esters |
2022-2-04 |
2022-5-19 |
|
| Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)- … |
2022-1-27 |
2022-4-12 |
|
| STABILIZED SUBMICROMETRIC PHARMACEUTICAL SUSPENSIONS AND METHODS FOR FORMING … |
2022-1-14 |
2023-4-19 |
|
| Neuroendocrine tumor treatment |
2022-1-14 |
2008-8-12 |
|
| Nlrp3 inflammasome inhibitors |
2022-1-13 |
2022-8-11 |
|
| Treatment of cancer using chimeric antigen receptor in combination with … |
2022-1-12 |
2022-4-19 |
|
| Fusion proteins for treating metabolic disorders |
2022-1-11 |
2022-4-12 |
|
| Weekly and monthly disposable water gradient contact lenses |
2022-1-11 |
2022-5-05 |
|
| Use of il-1beta binding antibodies |
2022-1-10 |
2022-12-08 |
|
| Pazopanib |
2022-1-06 |
2022-1-06 |
|